Merck KGaA

Merck and Pfizer’s Bavencio approved for renal cell carcinoma
Merck and Pfizer’s Bavencio approved for renal cell carcinoma
Pharmaforum
Merck KGaA
Pfizer
Bavencio
FDA
Inlyta
advanced renal cell carcinoma
Flag link:
Merck KGaA retools F-star pact, walks away from lead PD-L1 drug
Merck KGaA retools F-star pact, walks away from lead PD-L1 drug
Fierce Biotech
Merck KGaA
bispecific antibodies
f-star
drug discovery
Flag link:
German Merck finally gets yes for MS drug Mavenclad
German Merck finally gets yes for MS drug Mavenclad
Biopharma Dive
FDA
Merck KGaA
Mavenclad
MS
multiple sclerosis
Flag link:
Still hunting a blockbuster, Merck KGaA scores a win in the FDA approval column — more than 13 years in the making
Still hunting a blockbuster, Merck KGaA scores a win in the FDA approval column — more than 13 years in the making
Endpoints
FDA
Merck KGaA
cladribine
MA
multiple sclerosis
Flag link:
Merck KGaA injecting €150M into biologics site where it makes immunotherapies
Merck KGaA injecting €150M into biologics site where it makes immunotherapies
Fierce Pharma
Merck KGaA
Switzerland
drug manufacturing
biologics
Flag link:
Merck KGaA investing €1B at headquarters site as part of 5-year work agreement
Merck KGaA investing €1B at headquarters site as part of 5-year work agreement
Fierce Pharma
Merck KGaA
headquarters
Germany
Flag link:
Pfizer, Merck KGaA throw in the towel on another Bavencio PhIII as once bright hopes shrivel fast
Pfizer, Merck KGaA throw in the towel on another Bavencio PhIII as once bright hopes shrivel fast
Endpoints
Pfizer
Merck KGaA
ovarian cancer
Bavencio
Flag link:
Merck KGaA signs another AI deal
Merck KGaA signs another AI deal
Pharmaforum
Merck KGaA
artificial intelligence
Iktos
drug discovery
Flag link:
Merck KGaA admits to ‘challenging’ 2018, as currencies hit sales
Merck KGaA admits to ‘challenging’ 2018, as currencies hit sales
Pharmaforum
Merck KGaA
earnings
Flag link:
After Tesaro buy, GSK wades deeper into cancer unveiling big immunotherapy deal with Germany's Merck
After Tesaro buy, GSK wades deeper into cancer unveiling big immunotherapy deal with Germany's Merck
Endpoints
GSK
Merck KGaA
Tesaro
immunotherapy
Flag link:
Forget the suggestion box. Merck KGaA puts employee ideas on a TED stage
Forget the suggestion box. Merck KGaA puts employee ideas on a TED stage
Fierce Pharma
Merck KGaA
pharma employees
TED talks
Flag link:
Merck KGaA signs China digital health deal with Tencent
Merck KGaA signs China digital health deal with Tencent
Pharmaforum
Merck KGaA
Tencent
China
digital healthcare
artificial intelligence
Flag link:
Vertex sharpens focus on gene-editing in licensing deal with Merck KGaA
Vertex sharpens focus on gene-editing in licensing deal with Merck KGaA
Endpoints
Vertex Pharmaceuticals
Merck KGaA
gene editing
M9831
Flag link:
Bavencio fails second ovarian cancer Phase III trial
Bavencio fails second ovarian cancer Phase III trial
BioCentury
Merck KGaA
Bavencio
ovarian cancer
Flag link:
Merck KGaA hands off its CAR-T R&D operations to Intrexon in $175M deal
Merck KGaA hands off its CAR-T R&D operations to Intrexon in $175M deal
Endpoints
Merck KGaA
CAR-T
Intrexion
M&A
Flag link:
Merck's Keytruda puts heat on Pfizer, Merck KGaA's Bavencio with new Merkel cell OK
Merck's Keytruda puts heat on Pfizer, Merck KGaA's Bavencio with new Merkel cell OK
Fierce Pharma
Merck
Keytruda
Pfizer
Merck KGaA
Bavencio
Merkel cell carcinoma
Flag link:
Merck KGaA links with AI firm to iron out side-effects during R&D
Merck KGaA links with AI firm to iron out side-effects during R&D
Pharmaforum
Merck KGaA
R&D
artificial intelligence
Cyclica
drug development
Flag link:
Merck KGaA Partners With Startup for Image Tagging Software
Merck KGaA Partners With Startup for Image Tagging Software
Yahoo/Bloomberg
Merck KGaA
V7
artificial intelligence
Flag link:
Syntropy, a Merck KGaA – Palantir JV aiming to apply big data to cancer research
Syntropy, a Merck KGaA – Palantir JV aiming to apply big data to cancer research
GoinPharma
Merck KGaA
Palantir Technologies
Syntropy
cancer
Big Data
Flag link:
A Small Group of Pharma Companies Is Making the Bulk of Medicines Necessary for Developing Countries
A Small Group of Pharma Companies Is Making the Bulk of Medicines Necessary for Developing Countries
BioSpace
GSK
JNJ
Novartis
Merck KGaA
Sanofi
Takeda
developing countries
Flag link:

Pages